Tirzepatide (10 mg vial)
Once weekly subcutaneous protocol for metabolic and weight-management research.
Tirzepatide is a dual GIP and GLP-1 receptor agonist, approved for type 2 diabetes and chronic weight management, and it out-performed semaglutide head to head on weight loss in trials. The protocol below is the standard once-weekly subcutaneous escalation, stepping up every four weeks as tolerated.
Quick answer: at the standard 10 mg + 1 mL reconstitution, a 10 mg dose of Tirzepatide draws 100 units (1.0 mL) on a U-100 insulin syringe, once weekly subcutaneous.
Get Tirzepatide → code PEPDOSE
Protocol overview
Dosing & reconstitution
Frequency: Once weekly subcutaneous
Typical duration: 12-16+ weeks
Reconstitution: 10 mg vial + 1 mL bacteriostatic water = 10 mg/mL. Units below are for a U-100 insulin syringe at this concentration.
| Phase | Dose | Units per injection |
|---|---|---|
| Weeks 1-4 | 2.5 mg | 25 units (0.25 mL) |
| Weeks 5-8 | 5 mg | 50 units (0.5 mL) |
| Weeks 9-12 | 7.5 mg | 75 units (0.75 mL) |
| Weeks 13-16 | 10 mg | 100 units (1.0 mL) |
Units = (dose ÷ concentration) × 100 on a U-100 syringe. Change the vial size or water volume and the calculator redoes all of this for you.
Track this protocol → Free account · log doses, rotate sites, never lose your history
Tirzepatide dosing schedule
From the SURMOUNT-1 phase 3 obesity trial and the approved label, escalating in 2.5 mg steps at four-week intervals.
| Phase | Amount | Frequency | Notes |
|---|---|---|---|
| Weeks 1–4 | 2.5 mg | Once weekly | Lead-in step for tolerability. |
| Weeks 5–8 | 5 mg | Once weekly | Lowest of the three maintenance arms. |
| Weeks 9–12 | 7.5 mg | Once weekly | Escalation step only. |
| Weeks 13–16 | 10 mg | Once weekly | Second maintenance arm. |
| Weeks 17–20 | 12.5 mg | Once weekly | Escalation step only. |
| Week 21 onward | 15 mg | Once weekly | Highest maintenance arm. |
Study length: 72 weeks in SURMOUNT-1. Arms stopped escalating at 5, 10 or 15 mg.
Reconstitution and measurement
This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for Tirzepatide: 10, 20, 30, 60, 100, 120 mg.
- Wipe the stoppers of both vials with an alcohol swab and let them dry.
- Draw the bacteriostatic water with a sterile syringe and inject it slowly down the inside wall of the peptide vial — never straight onto the powder.
- Swirl gently until the solution is clear. Do not shake; foaming and agitation damage peptides.
- Label the vial with the date and concentration, and refrigerate at 2–8 °C protected from light.
Worked example at the calculator defaults: 30 mg + 3 mL of bacteriostatic water = 10 mg/mL, so on a U-100 insulin syringe 1 unit = 100 mcg of Tirzepatide. Change either input and the calculator redoes this for you.
Storage and stability
Supplies math
Whatever amounts your research uses, the planning arithmetic is the same. The calculator runs all of this per compound.
Supplies by protocol length
Based on the maintenance dose above (10 mg, once weekly subcutaneous) and a 10 mg vial reconstituted with 1 mL.
| Duration | Injections | Vials | Syringes | Bac water | Swabs |
|---|---|---|---|---|---|
| 8 weeks | 8 | 8 x 10 mg | 9 | 1 x 10 mL | 16 |
| 12 weeks | 12 | 12 x 10 mg | 14 | 2 x 10 mL | 24 |
| 16 weeks | 16 | 16 x 10 mg | 18 | 2 x 10 mL | 32 |
Syringe count includes ~10% spares. Swabs = 2 per injection (stopper + site). Vial count assumes the full maintenance dose for the entire duration.
Important notes
Practical considerations for consistency and safety.
- Use a new sterile insulin syringe for each injection and dispose in a proper sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation and avoid lipohypertrophy.
- Inject slowly and steadily; wait a few seconds before withdrawing the needle to ensure complete delivery.
- Administer on the same day each week for consistency. If a dose is missed, administer as soon as possible within a few days.
- The 10 mg vial size is standard for this compound. Reconstitute with 1 mL bacteriostatic water for a convenient concentration.
How Tirzepatide works
A single peptide that activates both the GIP and GLP-1 receptors. That dual mechanism is what separates it from semaglutide and is the leading explanation for the larger weight changes in head-to-head work.
Benefits & side effects
Potential benefits
- Greater weight loss than semaglutide in head-to-head trials
- Dual GIP/GLP-1 action for enhanced metabolic effects
- Improved insulin sensitivity
- Significant reduction in waist circumference
Possible side effects
- GI effects similar to semaglutide (nausea, diarrhoea)
- Reduced appetite
- Injection site reactions
- Slow escalation mitigates GI side effects
This list reflects published literature and community reports. Individual responses vary. Not medical advice.
Bloodwork worth tracking
The community-standard practice is a baseline panel before starting, a recheck 8 to 12 weeks in, and another after time off. For Tirzepatide, the markers most worth watching:
HbA1clipid panelCMPamylase/lipase
Typical time off: Taper off over 4-8 wks
Lab panels are how a research protocol stays honest: numbers move before symptoms do. Interpretation belongs with a clinician. Not medical advice.
Lifestyle factors
None of the literature above was run on a background of poor sleep and no protein. These variables move outcomes more reliably than any compound on this site.
- Protein in the 1.6 to 2.2 g/kg range preserves lean mass through any body-composition phase.
- Resistance training 2 to 4 days per week plus 150+ minutes of weekly aerobic work reinforces whatever the protocol is doing.
- Sleep is the recovery window: 7 to 9 hours at consistent times.
- Hydration matters more than usual on compounds with GI or flushing effects: 2 to 3 liters daily.
- Track the variables that matter: weigh-ins, measurements, photos, and labs at sensible intervals.
Subcutaneous technique and practical notes
General best practice from clinical injection guidance — the same fundamentals nurses are taught, none of it specific to any compound.
Quick answers
How many syringe units is a 10 mg dose of Tirzepatide?
At the standard reconstitution of 10 mg with 1 mL bacteriostatic water (10 mg/mL), a 10 mg dose draws 100 units (1.0 mL) on a U-100 insulin syringe.
How do you reconstitute Tirzepatide?
Add 1 mL of bacteriostatic water to the 10 mg vial for 10 mg/mL. Inject the water slowly down the inside wall of the vial, swirl gently without shaking, and refrigerate at 2 to 8 °C after mixing.
How long does a 10 mg vial of Tirzepatide last?
About 1 maintenance doses of 10 mg, roughly 1 week at once weekly subcutaneous.
Does Tirzepatide have human trial data?
Yes. The dosing on this page is anchored to published human research (Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity", NEJM 2022 (SURMOUNT-1)).
How does Tirzepatide work?
A single peptide that activates both the GIP and GLP-1 receptors. That dual mechanism is what separates it from semaglutide and is the leading explanation for the larger weight changes in head-to-head work.
Sourcing Tirzepatide
Whatever you are working with, the documentation matters more than the price. Ask for a batch certificate of analysis whose lot number matches the vial you actually receive — a COA for a different batch tells you nothing about yours.
Tirzepatide at Summit Research Supply → Grade a COA first
Summit is the supplier we feature and an affiliate link. Our COA checklist applies the same way to any vendor.
